Citigroup Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Neena Bitritto-Garg maintains a Neutral rating on ACADIA Pharmaceuticals and raises the price target from $21.6 to $27.
July 14, 2023 | 3:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup maintains a Neutral rating on ACADIA Pharmaceuticals and raises the price target from $21.6 to $27.
The news is directly related to ACADIA Pharmaceuticals. The raised price target indicates a positive outlook, but the maintained Neutral rating suggests that the stock is not expected to outperform the market in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100